English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/166072
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
DC FieldValueLanguage
dc.contributor.authorLópez-Rodríguez, Rosarioes_ES
dc.contributor.authorPérez-Pampin, Evaes_ES
dc.contributor.authorMárquez, Anaes_ES
dc.contributor.authorBlanco, Francisco J.es_ES
dc.contributor.authorJoven, Beatrizes_ES
dc.contributor.authorCarreira, P.es_ES
dc.contributor.authorFerrer, Miguel Angeles_ES
dc.contributor.authorCáliz, Rafaeles_ES
dc.contributor.authorValor, Laraes_ES
dc.contributor.authorNarváez, J.es_ES
dc.contributor.authorCañete, Juan D.es_ES
dc.contributor.authorOrdoñez, María del Carmenes_ES
dc.contributor.authorManrique-Arija, Saraes_ES
dc.contributor.authorVasilopoulos, Yiannises_ES
dc.contributor.authorBalsa, Alejandroes_ES
dc.contributor.authorPascual-Salcedo, Doraes_ES
dc.contributor.authorMoreno-Ramos, Manuel J.es_ES
dc.contributor.authorAlegre-Sancho, Juan-Josées_ES
dc.contributor.authorNavarro-Sarabia, Federicoes_ES
dc.contributor.authorMoreira, Virginiaes_ES
dc.contributor.authorGarcía-Portales, Rosaes_ES
dc.contributor.authorRaya, Enriquees_ES
dc.contributor.authorMagro-Checa, Cesares_ES
dc.contributor.authorMartín, J.es_ES
dc.contributor.authorGómez-Reino, Juan J.es_ES
dc.contributor.authorGonzález, Antonioes_ES
dc.date.accessioned2018-06-11T11:25:42Z-
dc.date.available2018-06-11T11:25:42Z-
dc.date.issued2018-05-07-
dc.identifier.citationPLoS ONEes_ES
dc.identifier.urihttp://hdl.handle.net/10261/166072-
dc.descriptionSupporting information:S1 Text. Information on selected previous studies and compatibility with the current study. It includes two tables. Table A: List of SNPs selected for this study with references and the corresponding quality control results in the current study. Table B: Characteristics of the patients included in previous studies compared with the current study. https://doi.org/10.1371/journal.pone.0196793.s001 (DOCX) S1 Dataset. Raw data with all the variables and patients considered in this study. https://doi.org/10.1371/journal.pone.0196793.s002 (XLSX)es_ES
dc.description.abstractGenetic biomarkers are sought to personalize treatment of patients with rheumatoid arthritis (RA), given their variable response to TNF inhibitors (TNFi). However, no genetic biomaker is yet sufficiently validated. Here, we report a validation study of 18 previously reported genetic biomarkers, including 11 from GWAS of response to TNFi. The validation was attempted in 581 patients with RA that had not been treated with biologic antirheumatic drugs previously. Their response to TNFi was evaluated at 3, 6 and 12 months in two ways: change in the DAS28 measure of disease activity, and according to the EULAR criteria for response to antirheumatic drugs. Association of these parameters with the genotypes, obtained by PCR amplification followed by single-base extension, was tested with regression analysis. These analyses were adjusted for baseline DAS28, sex, and the specific TNFi. However, none of the proposed biomarkers was validated, as none showed association with response to TNFi in our study, even at the time of assessment and with the outcome that showed the most significant result in previous studies. These negative results are notable because this was the first independent validation study for 12 of the biomarkers, and because they indicate that prudence is needed in the interpretation of the proposed biomarkers of response to TNFi even when they are supported by very low p values. The results also emphasize the requirement of independent replication for validation, and the need to search protocols that could increase reproducibility of the biomarkers of response to TNFi.es_ES
dc.description.sponsorshipFunding: This work was supported by the Instituto de Salud Carlos III (Spain) through grants [PI14/01651 and RD16/0012/0014 to AG; and PI12/01909 to JJG-R]. These grants are partially financed by the European Regional Development Fund of the EU (FEDER). R. L.-R. was supported by Instituto de Salud Carlos III (Spain) through a Postdoctoral Contract “Sara Borrell” [CD14/00186]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Sciencees_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsopenAccesses_ES
dc.titleValidation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritises_ES
dc.typeArtículoes_ES
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196793#sec011es_ES
dc.identifier.e-issn1932-6203-
dc.rights.licensehttps://creativecommons.org/licenses/by/4.0/es_ES
dc.relation.csices_ES
oprm.item.hasRevisionno ko 0 false*
Appears in Collections:(IPBLN) Artículos
Files in This Item:
File Description SizeFormat 
journal.pone.0196793.pdfResearch article863,27 kBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.